INTRODUCTION: The aim of this study was to collect data in France in @entity1 with @entity6950 -induced @entity882 who required parenteral anticoagulation and for whom other non- @entity6950 anticoagulant therapies were contraindicated including @entity1 with @entity177 , cross-reactivity to danaparoid or at high hemorrhagic risk. METHODS: A total of 20 @entity1 , of mean age 72        10  years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics. RESULTS: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen @entity1 (70  %) were in an intensive care unit during the course of the study. @entity1 were treated with @entity20806 for a mean duration of 8.5        6.1  days. The mean starting dose of @entity20806 was 0.77        0.45   g/kg/min. Platelet recovery was rapid. aPTT and anti-IIa activity assays were used to monitor the dose of @entity20806 . The mean baseline aPTT value was 45.0        9.8  sec and increased to 78.2        35.8  sec two hours after initiating @entity20806 . At this time mean @entity20806 concentration was 0.34        0.16 and 0.61        0.28   g/ml using ECT and TT measurements, respectively. New and/or extended @entity715 were reported in 25  % of @entity1 and major bleedings were documented in 15  %. Six @entity1 died due to their underlying medical condition. CONCLUSION: Considering its hepatic elimination and its short half-life, @entity20806 can be considered as a safe therapeutic option in HIT @entity1 at high hemorrhagic risk and with @entity177 , particularly in an ICU setting.

@entity20806 in the management of XXXX -induced @entity882 : a multicenter clinical trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity20806 :: ('MESH:C031942', 'Chemical') :: ['argatroban'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity6950 :: ('MESH:D006493', 'Chemical') :: ['heparin'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thromboses']
@entity6950 :: (MESH:D006493,Chemical) :: ['heparin']
